Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 5 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Valeritas Holdings Inc. | 19,800,000 | reported | 20 Dec 2018 | tx 9+150,000 |
| CTD HOLDINGS INC | 18,861,787 | reported | 31 Aug 2020 | tx 6+165,263 |
| KIORA PHARMACEUTICALS INC | 16,802,500 | reported | 29 May 2018 | tx 21+2,594,478 |
| Vaxart, Inc. | 10,350,000 | reported | 18 May 2020 | tx 24+200,000−8,793,308 |
| EnteroMedics Inc | 5,322,900 | reported | 10 Nov 2020 | tx 18+5,098,629−5,085,834 |
| TENAX THERAPEUTICS, INC. | 4,773,269 | reported | 18 May 2022 | tx 16+38,213,790−16,989,736 |
| VICAL INC | 3,200,000 | reported | 28 Jun 2018 | tx 45+2,008,695 |
| PAIN THERAPEUTICS INC | 1,651,340 | reported | 03 Oct 2018 | tx 3−512,660 |
| Rosewind CORP | 1,342,378 | reported | 29 Mar 2021 | tx 16+14,368,147−2,751,148 |
| ACHIEVE LIFE SCIENCES, INC. | 796,594 | reported | 11 Jun 2019 | tx 4−47,182 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 27 Jun 2023 | SALE | Avalo Therapeutics, Inc. | 937,404 | 0.52 USD | |
| 26 Jun 2023 | SALE | Avalo Therapeutics, Inc. | 2,746,138 | 0.61 USD | |
| 18 May 2022 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 2,072,538 | — | deriv |
| 18 May 2022 | OTHER | TENAX THERAPEUTICS, INC. | 2,072,538 | — | deriv |
| 18 May 2022 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 2,360,313 | — | deriv |
| 18 May 2022 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 4,773,269 | — | deriv |
| 18 May 2022 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 4,607,692 | — | deriv |
| 18 May 2022 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 10,596,027 | — | deriv |
| 18 May 2022 | OTHER | TENAX THERAPEUTICS, INC. | 4,607,692 | — | deriv |
| 18 May 2022 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 3,175,924 | — | deriv |
| 18 May 2022 | OTHER | TENAX THERAPEUTICS, INC. | 3,175,924 | — | deriv |
| 18 May 2022 | GRANT_AWARD | TENAX THERAPEUTICS, INC. | 10,596,027 | — | deriv |
| 18 May 2022 | OTHER | TENAX THERAPEUTICS, INC. | 4,773,269 | — | deriv |
| 18 May 2022 | OTHER | TENAX THERAPEUTICS, INC. | 2,360,313 | — | deriv |
| 24 Feb 2022 | PURCHASE | Avalo Therapeutics, Inc. | 100,000 | 0.80 USD | |
| 25 Feb 2022 | PURCHASE | Avalo Therapeutics, Inc. | 40,000 | 0.79 USD | |
| 11 Jan 2022 | PURCHASE | Avalo Therapeutics, Inc. | 16,003 | 0.96 USD | |
| 07 Jan 2022 | PURCHASE | Avalo Therapeutics, Inc. | 137,900 | 1.04 USD | first after silence |
| 10 Jan 2022 | PURCHASE | Avalo Therapeutics, Inc. | 491,097 | 0.99 USD | |
| 20 Mar 2021 | OTHER | Rosewind CORP | 6,959 | 0.00 USD | |
| 29 Mar 2021 | OTHER | Rosewind CORP | 0 | 0.00 USD | |
| 29 Mar 2021 | OTHER | Rosewind CORP | 2,085 | 0.00 USD | |
| 20 Mar 2021 | OTHER | Rosewind CORP | 0 | 0.00 USD | |
| 15 Apr 2021 | CONVERSION | Avalo Therapeutics, Inc. | 6,285,715 | 2.00 USD | |
| 15 Apr 2021 | CONVERSION | Avalo Therapeutics, Inc. | 0 | 0.00 USD |
1 purchase reported after at least 12 months of silence — most recent on 07 Jan 2022.